Myriad Genetics Inc (MYGN)

Return on total capital

		Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Earnings before interest and tax (EBIT)	US$ in thousands	—	-248,000	-123,700	-48,700	-194,800
Long-term debt	US$ in thousands	—	—	—	—	—
Total stockholders’ equity	US$ in thousands	701,100	783,200	885,800	967,800	881,000
Return on total capital		0.00%	-31.66%	-13.96%	-5.03%	-22.11%

December 31, 2024 calculation

Return on total capital = EBIT ÷ (Long-term debt + Total stockholders’ equity)
= $—K ÷ ($—K + $701,100K)
= 0.00%

Myriad Genetics Inc's return on total capital has exhibited fluctuations over the past five years. The company reported a negative return on total capital of -22.11% as of December 31, 2020, which improved to -5.03% by December 31, 2021. However, there was a decline in the return on total capital to -13.96% as of December 31, 2022, followed by a substantial decrease to -31.66% by December 31, 2023, indicating a significant decrease in efficiency in utilizing its capital.

In the most recent period, as of December 31, 2024, Myriad Genetics Inc reported a return on total capital of 0.00%, signaling a potential turnaround or stabilization in the company's capital efficiency. It is important for stakeholders to continue monitoring this metric to assess the company's ability to generate returns relative to the total capital employed.